Myhrvold Warns Picks and Shovels Cos to Stay Out of Drug Discovery | GenomeWeb

NEW YORK, Feb 21 - Faced with growing concern from investors about prospects for future profitability, a number of genomics tool makers, large and small, have recently announced plans to refashion themselves as drug developers.

But Nathan Myhrvold, the revered software visionary turned biotechnology venture capitalist, on Wednesday warned genomics software and tool companies against rushing into the field of drug discovery.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PLOS this week: nasal microbial communities in asthma patients; sequencing-based way to detect, track schistosomiasis; and more.

The New York Times speaks with Vanderbilt's John Anthony Capra about Neanderthal genes in modern humans.

A draft guidance from the FDA suggests the agency wants to more tightly control gene-edited animals, according to Technology Review.

Researchers were among this weekend's protesters bemoaning the new US administration, Vox reports.